Related Experiment Videos
CVT-510: a selective A1 adenosine receptor agonist
1Division of Cardiology, Cornell University Medical Center-New York Presbyterian Hospital, New York, NY 10021, USA.
Cardiovascular Drug Reviews
|December 4, 2003
Summary
Adenosine effectively treats paroxysmal supraventricular tachycardia (PSVT) by targeting the atrioventricular node. A new drug, CVT-510, selectively activates A1 adenosine receptors, offering a potentially safer alternative for PSVT termination and rate control.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Adenosine, an endogenous nucleoside, exhibits potent antiarrhythmic properties by affecting the atrioventricular node.
- Adenosine exerts diverse physiological effects mediated by four receptor subtypes (A1, A2A, A2B, A3).
- A1 receptor activation is crucial for adenosine's negative chronotropic and dromotropic effects, relevant to cardiac rhythm control.
Purpose of the Study:
- To introduce CVT-510, a selective A1 adenosine receptor agonist.
- To evaluate CVT-510's efficacy in terminating paroxysmal supraventricular tachycardia (PSVT).
- To explore CVT-510's potential for controlling ventricular rate in atrial fibrillation and flutter.
Main Methods:
- Development of CVT-510 as a selective A1 adenosine receptor agonist.
- Preliminary clinical trials assessing CVT-510's effectiveness in PSVT termination.
- Investigation into CVT-510's role in managing atrial fibrillation and flutter rates.
Main Results:
- CVT-510 demonstrated effectiveness in terminating PSVT during preliminary clinical trials.
- CVT-510 showed a reduction in adverse effects compared to adenosine.
- CVT-510 is under investigation for controlling ventricular rates in atrial fibrillation and flutter.
Conclusions:
- CVT-510 is a promising therapeutic agent for PSVT termination.
- CVT-510 offers a potentially improved safety profile over adenosine.
- CVT-510 may have broader applications in managing cardiac arrhythmias.